Search Result for : Sanofi

The Dollar Business Bureau Sanofi-Synthelabo (India) Private Limited, Mumbai, a division of Sanofi announced the launch of two drugs Lyxumia and Zemiglo for type 2 diabetes patients in India. Lyxumia a non-insulin injectable drug, is prescribed once daily and Zemiglo, an oral tablet is prescribed to be taken once in a day. India is home to second largest number of diabetics after China in the world. The International Diabetes Federation Diabetes Atlas 2015, says India has 69.1 million diabetic patients which is expected to rise to 140 million in 2040. And 1 million deaths in India occur only due to diabetes. These alarming statistics reveal the diabetic epidemic that India is undergoing right now. Counter measures in the form of diet, exercise and ...

Sheela Mamidenna On June 23rd, at around 3pm the 1st Edition of The Dollar Business Power Series Conclave concluded amidst much energy and enthusiasm. It was a meeting point for the best minds in the business and trade industry in India and the world to contemplate, deliberate and gather answers on “WHY MAKE’IN’G INDIA AN EXPORT MANUFACTURING SUPERPOWER IS THE NEED OF THE HOUR! Among the noted personalities invited to address the attendees, was Dr. Mahesh Bhalgat, Executive Director & COO, Shantha Biotechnics - A Sanofi Company. The Dollar Business correspondent had the opportunity to catch up with him and take his views on the future prospects of his company, the tough competition that pharma products withstand and the company’s transition ...

Sharath Chowdary Shantha Biotechnics has started commercial production of its new manufacturing unit in Muppireddipalli Special Economic Zone (SEZ) near Hyderabad. With an investment of over Rs.250 crore, the new facility has been built to produce and export vaccines to the United Nations Children's Emergency Fund (UNICEF) and other international markets. The company is completely owned by Sanofi Pasteur, the vaccines division of French pharma company Sanofi Group. Another manufacturing facility is also being set up in Hyderabad with an investment of Rs.450 crore for the production of Insuman, human insulin, used in the treatment of diabetes. This plant is expected to commence its operations next year, Varaprasad Reddy, Chairman of Shantha Biotechnics told The Dollar Business.  He said, “The two facilities are ...